

Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A-Details of the Acquisition

Name of the Target Company (TC)	Sun Pharmaceutical Industries Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer: Daiichi Sankyo Company, Limited		
Whether the acquirer belongs to Promoter/ Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1) BSE Ltd. 2) National Stock Exchange of India Ltd.		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC(**)
Before the acquisition under consideration, holding of acquirer along with PAC of :			
a) Shares carrying voting rights	Nil	Nil	Nil
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	Nil	Nil	Nil
c) Voting rights (VR) otherwise than by equity shares	Nil	Nil	Nil
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
e) Total (a+b+c+d)	Nil	Nil	Nil
Details of acquisition			
a) Shares carrying voting rights acquired	214,969,058	8.93%	8.93%
b) VRs acquired otherwise than by shares	Nil	Nil	Nil
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	Nil	Nil	Nil
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	Nil	Nil	Nil
e) Total (a+b+c+-d)	214,969,058	8.93%	8.93%
After the acquisition holding of acquirer along with PACs of:			
a) Shares carrying voting rights	214,969,058	8.93%	8.93%
b) VRs otherwise than by shares	Nil	Nil	Nil
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying	Nil	Nil	Nil

voting rights in the TC (specify holding in each category) after acquisition			
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	Nil	Nil	Nil
e) Total (a+b+c+d)	214,969,058	8.93%	8.93%
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/ encumbrance etc).	Acquisition upon allotment of shares pursuant to effectiveness of the amalgamation of Ranbaxy Laboratories Limited pursuant to the Scheme of Amalgamation of Ranbaxy Laboratories Limited with Sun Pharmaceutical Industries Limited, under Sections 391-394 of the Companies Act, 1956 ("Scheme")		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	N.A.		
Date of acquisition of / date of receipt of intimation of allotment of shares / VR/ warrants/ convertible securities/ any other instrument that entitles the acquirer to receive shares in the TC.	16 th April, 2015, being the date of acquisition of shares		
Equity share capital / total voting capital of the TC before the said acquisition	Rs. 2,071,163,910 fully paid-up equity shares of face value Rs. 1/- each.		
Equity share capital/ total voting capital of the TC after the said acquisition	Rs. 2,406,120,674 fully paid-up equity shares of face value Rs. 1/- each.		
Total diluted share/voting capital of the TC after the said acquisition	Rs. 2,406,120,674 fully paid-up equity shares of face value Rs. 1/- each.		

For Daiichi Sankyo Company, Limited

Manabu Sakai

Manabu Sakai

Representative Director

Place: 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 103-8426, Japan

Date: 16th April, 2015

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***)Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.